Naftin Gel, Cream 2% Approved for Pediatric Use
Merz Dermatology announced that Naftin (naftifine HCl) Gel 2% and Naftin (naftifine HCl) Cream 2% have been approved for the treatment of interdigital type tinea pedis in pediatric patients aged 12–17 years. Both Naftin Gel and Cream 2% were initially approved for use in patients ≥18 years old.
The expanded approval of Naftin Gel and Cream 2% in pediatric patients was based on results from clinical trials involving 4 investigational sites (n=44). Study results showed patients treated with Naftin Gel 2% and Naftin Cream 2% demonstrated clinically significant cure rates compared to placebo.
Naftin is an allylamine antifungal that appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene 2, 3-epoxidase. This enzyme inhibition results in decreased amounts of sterols, especially ergosterol, and a corresponding accumulation of squalene in the cells.
For more information call (877) 743-8454 or visit Naftin.com.